Literature DB >> 22491346

Why do phase III clinical trials in oncology fail so often?

Laleh Amiri-Kordestani, Tito Fojo.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22491346     DOI： 10.1093/jnci/djs180

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  17 in total

1.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

Review 2.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

Review 3.  Appraising iniparib, the PARP inhibitor that never was--what must we learn?

Authors:  Joaquin Mateo; Michael Ong; David S P Tan; Michael A Gonzalez; Johann S de Bono
Journal:  Nat Rev Clin Oncol       Date:  2013-10-15       Impact factor: 66.675

4.  Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials.

Authors:  Robert S Kerbel; Axel Grothey
Journal:  Nat Rev Clin Oncol       Date:  2015-05-12       Impact factor: 66.675

Review 5.  The development of dendritic cell vaccine-based immunotherapies for glioblastoma.

Authors:  David A Reardon; Duane A Mitchell
Journal:  Semin Immunopathol       Date:  2017-01-30       Impact factor: 9.623

6.  Preclinical models for interrogating drug action in human cancers using Stable Isotope Resolved Metabolomics (SIRM).

Authors:  Andrew N Lane; Richard M Higashi; Teresa W-M Fan
Journal:  Metabolomics       Date:  2016-06-29       Impact factor: 4.290

Review 7.  Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system.

Authors:  James D Guest; John D Steeves; M J Mulcahey; Linda A T Jones; Frank Rockhold; Rϋediger Rupp; John L K Kramer; Steven Kirshblum; Andrew Blight; Daniel Lammertse
Journal:  Spinal Cord       Date:  2020-09-16       Impact factor: 2.772

8.  Designing of phenol-based β-carbonic anhydrase1 inhibitors through QSAR, molecular docking, and MD simulation approach.

Authors:  Shahzaib Ahamad; Md Imtaiyaz Hassan; Neeraja Dwivedi
Journal:  3 Biotech       Date:  2018-05-14       Impact factor: 2.406

9.  The Impact of Early-Phase Trial Design in the Drug Development Process.

Authors:  Mark R Conaway; Gina R Petroni
Journal:  Clin Cancer Res       Date:  2018-10-16       Impact factor: 12.531

10.  The misguided ethics of crossover trials.

Authors:  Vinay Prasad; Christine Grady
Journal:  Contemp Clin Trials       Date:  2013-12-21       Impact factor: 2.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.